Knightsbridge Asset Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Knightsbridge Asset Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,011	Closed	-$8K	–	142
2022 Q3	$8K	Sell	1,011 -106	-9%	-$1.75K	﹤0.01%	119
2022 Q2	$23K	Buy	1,117 +591	+112%	+$13.9K	﹤0.01%	118
2022 Q1	$20K	Buy	+526	New	+$18.2K	0.01%	97

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Knightsbridge Asset Management's NBSE Position: Q4 2022 in Review

Knightsbridge Asset Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 1,011 shares — an estimated $8K sold.

Knightsbridge Asset Management first reported a position in NBSE in Q1 2022 and held it in 3 quarters. The position peaked at $23K in Q2 2022. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

Knightsbridge Asset Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Knightsbridge Asset Management sold 1,011 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $8K.
Knightsbridge Asset Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Knightsbridge Asset Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $23K in Q2 2022.
34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Knightsbridge Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.